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USE OF MEDIA TO IMPROVE HUMAN PAPILLOMA VIRUS (HPV) VACCINE 
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Pavithra Venkat, Ella Chapman, Emily Ko, and Elizabeth Garner. Department of Obstetrics and 
Gynecology, Brigham and Women’s Hospital, Boston, MA. (Sponsored by Jessica Illuzzi, 
Department of Obstetrics and Gynecology, Yale University School of Medicine). 
 
Our objective was to determine if using a video educational tool can influence (1) individual 
vaccine acceptability (2) parental acceptability, (3) parental views on vaccine mandates, and (4) 
age of vaccination accepted for the Human Papilloma Virus (HPV) vaccine. We conducted a 
cross-sectional study using bilingual surveys distributed at Brigham and Women’s and 
Massachusetts General Hospital clinics and at the Coalition of Boston Public Health Association 
from January to March 2007.  An initial 32-question survey addressing HPV knowledge, beliefs 
and vaccine acceptability was completed, followed by an eight-minute video about HPV and the 
vaccine. An additional 11-question post assessment was then completed. Five questions were 
extracted from both the pre/post questionnaires to evaluate HPV vaccine acceptability. Out of 256 
subjects, 186 (73%) completed the video intervention and pre/post surveys.  Of the 186, 66.6% 
(124) of subjects said they would vaccinate themselves.  Individual acceptability increased after 
the video to 78% (p=.0014).  An additional 55.8 % (102/186) of subjects supported making the 
HPV vaccine required for all children, with 51.1% (95/186) supporting vaccination if it were 
given at school and 66.7% (124/186) supporting child vaccination if it were free.  After the video, 
this increased to 72.6%  (p<.0001), 65.1%  (p<.0001) and 86.6%  (p<.0001) respectively.  
Initially, 56.5% (105/186) of subjects would vaccinate their child only if the child were older than 
15 years of age; post-intervention, 82.3% of subjects accepted vaccination starting at age 9 and up 
(p<.0001).  Secondary analysis revealed that Hispanic, Blacks and those with combined income 
less than $50,000 were more likely to not initially accept HPV vaccine for their children but 
showed high rates of acceptability after intervention. People’s perception that vaccination will 
promote sex amongst the young was significant but did not affect overall acceptability. In 
conclusion, using multi-media as a way to increase knowledge significantly increased individual 
acceptability, parental acceptability, and age of acceptance of the HPV vaccine.  
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I. Introduction 
The approval of the quadrivalent Human Papilloma virus (HPV) vaccine 
(Gardasil© - HPV 6, 11, 16, 18) in June 2006 by the US Food and Drug Administration 
represented a landmark step in the prevention of cervical cancer. Persistent infection with 
certain subtypes of HPV has long been known to be associated with both cervical cancer 
and genital warts.  A reduction in the acquisition of HPV could significantly lower the 
incidence of future high grade cervical lesions and reduce condylomatous disease. (1, 2) 
In order to achieve a reduction in population prevalence of HPV, full series vaccination 
of girls aged 11 to 26 is needed. Public health interventions that focus on understanding 
barriers and improving acceptability towards vaccination will be important in helping to 
achieve target levels of vaccination.  
A. Incidence, Prevalence & Risk Factors 
HPV is the most common sexually transmitted infection in the United States. Data 
from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 
suggests the prevalence of HPV infection to be as high as 26.8% (95% CI, 23.3%-30.9%) 
in a representative sample of 1,921 American women aged 14-59. (3) The NHANES 
group found a combined prevalence of the four vaccine types targeted by the quadrivalent 
vaccine (6, 11, 16 &18) of 3.4% and a combined prevalence of oncogenic subtypes 16 
&18 of approximately 2%.  Most notably, the study found that prevalence rose between 
the ages of 14-24 and then gradually declined until age 59, suggesting that younger 
women are at higher risk for acquiring HPV.  [Figure 1] 
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A second study, the National Longitudinal Study of Adolescent Health 
(ADHEALTH), looked specifically at US adolescents aged 18 to 25 and found a 
combined prevalence in this group of 26.9%. The ADHEALTH study identified a 
significantly lower prevalence in youth than the 49.3% prevalence of HPV infection in 
the 20 to 24 year old subgroup of the NHANES study. In their JAMA editorial, authors 
Weller and Stanberry (4)remark on this discrepancy (while noting the limitations in exact 
comparison between the two studies) and suggest that the method of viral detection – 
using urine samples in ADHEALTH vs. cervico-vaginal swabs in NHANES – could 
account for an underestimation of prevalence amongst younger women in ADHEALTH.  
 
Figure 1. From
 D
unne, et al (3) 
 3
Independent risk factors for HPV acquisition in the NHANES study included age, 
marital status, and increasing number of lifetime and recent sexual partners. Of note, 
HPV prevalence in Black women was 39.2% versus 24.2% in non-Hispanic Whites and 
24.3% in Mexican American women (p<0.001). (3) However, while race was a risk 
factor for HPV in bivariate analysis, this did not prove the case in the multivariate model. 
Further work on the NHANES data by Kahn et al (5) demonstrated that women living 
below the poverty line were more likely to be infected with a high-risk subtype of HPV 
than those living three or more times above it. One possible conclusion from this data is 
that socioeconomic status or other confounding factors and not race could account for the 
above differences in prevalence in Black women. In multivariate analyses of both studies, 
educational level was not associated either positively or negatively with HPV infection.  
Given the natural history of HPV – exposure followed by viral clearance in the 
majority of women– it is logical to assume that a peak in infection would occur in women 
around the age of sexual debut and first exposure to the virus. It is also important to note 
that any study of prevalence will count a large number of infections that will clear on 
their own; only a small percentage of these persist, and it is these persistent infections 
that lead to pre-cancerous changes. 
B. Establishing the connection between HPV and Cervical Cancer 
Papillomaviruses have evolved to survive in the various transformation zones of 
the body and different subtypes have been linked to oropharyngeal, cervical, and 
anogenital cancers. The majority of cervical cancers arise in an area of the cervix called 
the transformation zone, so named because of the junction of stratified squamous 
epithelium of the ectocervix with the columnar epithelium of the endocervix. (6)  
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HPV types 16 and 18 are the subtypes most commonly linked to cervical cancer in the 
United States and the developed world. Together they are responsible for about 70% of 
cervical cancer and approximately 50% of cervical intraepithelial neoplasia (CIN) grade 
3. Infection with two other subtypes of HPV, 6 and 11, accounts for 90% of genital warts. 
HPV subtype 16 is predominantly associated with the more common squamous cell 
cancers, while HPV type 18 has been strongly linked to adenocarcinomas arising from 
columnar glandular cells. Recent data suggests that cervical adenocarcinoma incidence 
has not decreased at the same rate as squamous cell carcinomas; this may in part be due 
to the fact that these cancers are located in the more internal columnar cells of the cervix 
and thus more often escape detection during PAP smears. Adenocarcinomas are also 
attributed with different risk factors and show different patterns of progression than 
squamous cell carcinomas.(7) 
Transmission of HPV occurs through micro-tears in the mucosa, most commonly 
during sexual intercourse. Research suggests that the viral particles can travel from the 
vaginal introitus to reach cervical cells, suggesting that penetrative sexual intercourse is 
not necessary for transmission. Interestingly, some additional data suggests that male 
circumcision may reduce transmission of HPV; a proposed theory suggests keratinized 
penile epithelium may impede mucosal transfer.  (6) 
The HPV viral genome consists of only eight genes. Initial studies suggest that the 
mechanism of viral action for HPV involves two specific proteins, E6 and E7, which are 
encoded by the HPV genome (see Figure 2). E6 and E7 are onco-proteins with multiple 
cellular targets, most notably the p53 and retinoblastoma tumor suppression proteins 
(pRB) respectively. Inhibition of p53 by E6 leads to blockage of apoptosis, and inhibition 
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of pRB by E7 leads to cell cycle arrest. These proteins are expressed at low levels during 
infection. At a point during viral persistence deregulation occurs, leading to over-
expression of the proteins in full thickness epithelium and subsequent changes in the cell 
cycle that lead to the development of pre-cancerous changes. (8) 
Figure 2 Adapted from Schiffman, et al. (6) 
 
 
C. Progression to Cancer 
Approximately 30% of women newly infected with HPV show some 
abnormalities in cervical cytology. The majority of women will clear the infection within 
2 years. However, in a subset of approximately 10% of these women, viral persistence 
occurs with a clone of infected cells that eventually progress to pre-cancer. Abnormalities 
detected on Pap that persist for greater than one year are therefore most concerning for 
pre-cancerous change. Of the HPV subtypes, HPV 16 is the most oncogenic, with a 40% 
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absolute risk of progression to pre-cancer if infected persistently for 3-5 years. Of note 
smoking, multiparity, and long term use of oral contraceptives (OCPs) can double to 
triple the rate of progression to pre-cancer. (6) Women with HIV also show increased 
viral persistence and longer time to clearance of HPV infections and may be at increased 
risk for progression to pre-cancer. 
Abnormalities of the cervix are characterized by either cytological diagnosis 
(typically by a PAP smear) or a histological diagnosis. The cytological classification 
scheme includes the following designations: LSIL (Low Grade Squamous Intraepithelial 
Neoplasia), HSIL (High Grade Intraepithelial Neoplasia), ASC-US (Atypical Squamous 
Cells of Undetermined Significance) and ASC-H (Atypical Squamous Cells cannot 
exclude High Grade Lesion). The histopathological classification scheme includes the 
diagnoses of cervical intraepithelial neoplasia (CIN) Grades 1 through 3. It is important 
to realize that though a large number of pre-cancers are detected, not all of these will 
progress to invasive cancer. For further explanation of the significance, rates of 
progression, and management of lesions based on the above schemata, please refer to the 
following tables. 
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Table 1 Histological Classification and Management of Cervical Intra-epithelial Neoplasia1,2 
CIN 3 
Severe 
Dysplasia 
or 
Dyskaryosis 
Carcinoma 
in Situ 
Pre-Cancer • 32-47% 
spontaneous 
regression 
• 12-36% to 
invasive cancer 
CIN 2 Equivocal – can be 
produced by non-
carcinogenic HPV 
types. Data 
suggests 43-48% 
regress if untreated, 
22% progress to 
CIN 3, 5% to 
invasive cancer 
• 43-48% 
regression 
• 22% progression 
to CIN 3 
• 5% progression 
to invasive CA 
Excision or Ablation of T-
zone 
Then: 
• PAP or PAP+Colpo 
@4-6 mos (3 – then go 
to annual) 
• Or HPV @ 6mos (if – 
go to annual PAP) 
• If ASC, SIL, or HPV+ 
then repeat colposcopy 
CIN 1 Insensitive 
Histopathological 
sign of HPV 
Infection, one study 
suggests 51% 
regress.  
• 47% regression 
• 21% progression 
to high grade 
• 0.15% to 
invasive CA 
• Serial pap at 6 & 12 
mos  (2 – smears, 
return to annual, ASC 
or grtr Æcolpo) 
• Or HPV test in 12 mos 
with referral to colpo if 
+ (if – go to annual 
Pap) 
• If post-menopausal or if 
fertility irrelevant, can 
go to excision. 
 
Table 2 Cytological Classification and Management of Pre-Cancerous Changes 1,2 
LSIL Roughly 
corresponds to 
CIN 1, 15% risk 
of underlying 
CIN 2,3.  
• 47% regress 
• 21% progress to high 
grade lesion 
• 0.15% to invasive 
cancer @ 24 mos 
Referral to Colposcopy +/- 
ECC  
Post Menopausal Women & 
Adolescents: 
• Serial cytology in 6 & 
12 mos  
• or HPV in 12 mos. 
HSIL Roughly 
corresponds to 
CIN 2,3 (70-
75% risk) 
• 35 % regress 
• 1.4% to invasive CA 
@24 mos 
Referral to Colposcopy +/- 
ECC  
• If Colpo negative still 
recommend excision 
Adolescents  
• can have repeat 
                                                 
1 Information compiled from Up to Date, American Society for Colposcopy & Cervical Pathology 
(ASCCP) Consensus Guidelines, and American College of Obstetricians and Gynecologists Guidelines. 
Progression rates from (38, 39). Note: Colpo = Colposcopy. PAP = Papanicolou test. ECC= Endo-
Cervical Curretage 
 
2 Management may differ in HIV patients. 
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colpo+ECC at 6 mos- 
1 yr 
ASC – 
US  
 
ASC – H   
Atypical 
Squamous 
Cells of 
Undetermined 
Significance 
 
Atypical 
Squamous 
Cells Cannot 
Exclude High 
Grade Lesion 
• 68 % regression 
• 7 % progression to high 
grade lesion 
• 0.25% invasive CA @ 
24 mos 
 
 
The average age of detection of those with viral persistence and precancerous 
changes is 10 years after sexual debut, which in the Untied States means peak detection 
of pre-cancerous changes at ages 25 to 35 years of age. The peak age range for detection 
of invasive cancers is subsequently age 35 to 55. It is important to note that the time 
between acquisition of HPV infection and the development of cancer can exceed 20 
years.  
HPV genetic testing is now available and is being utilized alongside PAP smears 
for detection and management of lesions. Screening with the HPV test can catch pre-
cancerous changes often earlier than either cytology or colposcopy can, but also leads to 
the identification of a large number of changes related to recent infections which may 
clear on their own with time. Current American Cancer Society and American College of 
Obstetricians and Gynecologists (ACOG) recommendations suggest utilization of the 
HPV test as an adjunct to Pap screening in women over 30 (with a negative test leading 
to greater intervals between Pap testing) or in triage of women with equivocal ASC-US 
lesions on Pap smear.  
There is still a great deal to be learned about the pathway of progression to 
cervical cancer. For example, research is unclear whether women do truly clear HPV 
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infections, or whether the virus can persist in a latent stage. The preponderance of HPV 
positivity in HIV patients may suggest that a latent stage is reactivated when the immune 
system is weakened. Studies must also substitute CIN II and II as surrogate markers for 
cervical cancer, since the standard of care requires treatment of lesions before they 
progress to cancer. 
D. Epidemiology of Cervical Cancer 
The American Cancer Society estimates that 11,150 cases of cervical cancer are 
diagnosed each year in the United States. Non-invasive cervical cancer (carcinoma in 
situ) is approximately 4 times more common than invasive cancer.(9)  It is estimated that 
in 2007 about 3,670 women will die from cervical cancer. Death rates from cervical 
cancer have declined significantly in the last forty years as a result of increased use of the 
Papanicolou screening test and experts predict that they will continue to decline at a rate 
of approximately 4 % a year. Cervical cancer tends to disproportionately affect the 
worlds poorest regions; over 80% of cases occur in developing nations in Latin America, 
Sub-Saharan Africa, and India.(10) 
Cervical cancer is clinically staged with the FIGO (International Federation of 
Gynecology and Obstetrics) System of Staging [Table 4]. This system classifies the 
disease in stages 0 through IV as determined by clinical spread of disease. Clinical spread 
is determined by a combination of physical examination, colposcopy, histopathology (on 
biopsy or conization), radiography (chest x-ray; CT, MRI, and PET to determine lymph 
node involvement), and endoscopy (cystoscopy or sigmoidoscopy). One randomized 
controlled trial evaluated surgical staging versus clinical staging and found no 
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difference(11); however, other evidence suggests improved results with surgical 
staging(12). 
 In the future FIGO recommendations may be modified to incorporate surgical 
staging; however, at present, especially given the preponderance of cervical cancer in 
developing countries without access to technology, the FIGO system remains clinically 
based. A rough guide to staging is as follows: Stage I (subdivided into IA1,IA2,IB1,IB2) 
corresponds to lesions confined to the cervix, Stage II (IIa,IIb) with spread to the vagina 
and then pelvis but not the lower 1/3 of the vagina or the pelvic side wall, Stage III 
(IIIa,IIIb) with spread into the lower third of the vagina or the pelvic wall, and Stage IV 
with spread to other organs.  
The five year survival rate for the earliest stages (I-II) of invasive cervical cancer is 80-
95% and 60% for Stage III.(10) The combined overall survival rate for all stages is 76%. 
(9) Treatment options typically involve some combination of surgery, chemotherapy, and 
radiation therapy [Table 3]. 
With this relatively high survival rate (in developed countries where access to 
surgery and radiation therapy is possible), the question arises as to the cost effectiveness 
and need for a mandatory vaccination. However, as discussed in the following sections, 
the vaccine may also have great cost-saving potential in terms of the millions of dollars 
spent on screening and treatment of abnormal cervical lesions in the United States. 
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3 Adapted from (10) 
Table 3 International Federation of Obstetrics and Gynecology (FIGO) Clinical Staging 
and Management of Cervical Cancer 3 
Stage Description General Management 
IA1 Invasive carcinoma, confined to cervix, diagnosed 
only by microscopy. Stromal 
invasion ≤3 mm in depth and ≤7mmin horizontal 
spread 
• Hysterectomy or 
Conization 
• Possible Radical 
Surgery or Radiation if 
Lymphovascular 
Involvement  
IA2 Invasive carcinoma, confined to cervix, diagnosed 
only by microscopy. Stromal 
invasion >3 mm and ≤5 mm in depth and ≤7 mm in 
horizontal spread 
IB1 Invasive carcinoma, confined to cervix, microscopic 
lesion >IA2 or clinically visible lesion ≤4 cm in 
greatest dimension 
IB2 Invasive carcinoma, confined to cervix, clinically 
visible lesion >4 cm in greatest dimension 
IIA Tumor extension beyond cervix to vagina but not to 
lower third of vagina. No parametrial invasion 
• Radical 
Hysterectomy for 
ovarian preservation 
(+adjuvant chemo- 
radiotherapy if risk 
factors) or 
• Radiotherapy  
(outcomes similar) 
• Radical 
Trachelectomy + 
Pelvic 
Lymphadenectomy 
for preservation of 
fertility  
• Possible future for 
Sentinel Node 
Biopsy = Straight to 
radio-chemotherapy 
without radical surgery 
IIB Tumor extension beyond cervix. Parametrial invasion 
but not to pelvic side wall and not to lower 
Third of vagina 
IIIA Tumor extension to lower third of vagina but not to 
pelvic side wall 
IIIB Tumor extension to pelvic side wall or causing 
hydronephrosis or non-functioning kidney 
IVA Tumor invasion into bladder or rectum 
• Chemo-Radiotherapy 
(platinum based) then 
possible surgery 
IVB Distant metastasis • Palliative 
Chemotherapy 
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E. Development of HPV Vaccines 
There are currently two HPV Vaccines developed for primary vaccination, 
Gardasil (© Merck) and Cervarix (© GlaxoSmithKline). While both target the oncogenic 
HPV Subtypes 16 and 18, Gardasil also offers additional protection from HPV 6 and 11, 
subtypes which are common causes of genital warts. Both vaccines consist of virus-like-
particles (VLPs), in this case the recombinant L1 protein of HPV expressed in yeast and 
self-assembled into non-infectious capsids. Intramuscular injection of the vaccine leads to 
production of high titers of neutralizing antibody, which are subsequently secreted into 
the vagina and cervix where they target HPV.  
As of 2007 four major randomized, double-blind, placebo controlled studies have 
evaluated the efficacy of the HPV vaccines: one phase II study of the monovalent HPV 
16 vaccine in 16-23 year olds (protocol 005), one phase II study of the quadrivalent 
vaccine in 16-23 year olds (protocol 007), and two phase III studies (protocols 013 and 
015) of the quadrivalent vaccine in 16-23 and 16-26 year olds respectively. (13-15)The 
two phase II studies evaluated the efficacy of the vaccine on persistent infection with 
HPV, and the phase III studies took this one step further and looked at the effect on 
clinical lesions (CIN, Vaginal Intraepithelial Neoplasia (VIN), genital warts). Of note 
these clinical lesions must serve as surrogate endpoints for the effect of the vaccine on 
cervical cancer since current standards of care require pre-cancerous lesions to be treated 
before progression to cancer can be verified.   
Table 4 CDC Recommendations of the Advisory Committee on Immunization Practice 
(ACIP): A Summary of Vaccine Efficacy Studies (16) 
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The vaccines were found to be highly effective. In fact, the combined efficacy of 
the trials against HPV 16 or 18 related CIN 2/3 or Adenocarcinoma in Situ (AIS) was 
100% (CI 92.9-100.0). The efficacy against CIN 1 as well as the above was 95.2% (87.2-
98.7), and the combined efficacy against subtype related genital warts was 98.9% (CI 
93.7-100.0). (16)  
The efficacy in the phase III trials was detected up to four years after initial 
vaccination; studies are ongoing to determine longer term efficacy. One phase II study 
showed a decline in antibody levels at 24 months followed by a plateau but maintained 
that antibody levels were still much higher than placebo or levels associated with 
previous infection.  Another Phase II trial aims to follow Nordic women for at least 14 
years with serologic testing for HPV at 5 and 10 years after vaccination. (16) Critics of 
compulsory vaccination point to the limitation of the time of follow up of current studies; 
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it is unclear as of now how long immunity persists and whether women may require a 
booster shot down the line.  
In addition the data on the effect of vaccination on women already infected with 
one or more types of HPV is limited; initial data suggests that in women who are already 
HPV subtype DNA positive at baseline, the vaccine is significantly less effective (CIN 
preventive efficacies ranging from 39-47%).  However, studies of antibody protection do 
show a boost after administration of the vaccine in women who already have natural 
immunity to a sub-type of HPV infection. (14) 
F. Vaccination Guidelines 
Gardasil is currently the only vaccine approved in the United States and has been 
approved for ages 9-26. Recommendations by the CDC Advisory Committee on 
Immunization Practice (ACIP) are for vaccination of girls 11 to 12 years of age, although 
the vaccine has been approved for ages 9 and above. (16)Catch up vaccination for girls 
aged 13 to 26 is recommended; however, the vaccine is most effective if given before 
sexual exposure and will have limited to no benefit in women who already have one or 
more of the subtypes of HPV found in the vaccine.  
The vaccine is given in three doses at with the second and third doses 
administered 2 and 6 months after the first respectively. It has been approved for 
simultaneous administration with age-related Meningococcal vaccine and the Tdap 
booster.  At this time immunogenicity and safety data is available on vaccination of men, 
but trials looking at efficacy are pending. The vaccine is not recommended for pregnant 
women, and has been classified as Category B in pregnancy based on animal studies. 
G. Impacts of Vaccination 
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Estimates suggest that the prevention and treatment of anogenital warts and HPV 
related disease in the United States results in $4 billion or more in direct costs each year. 
Of this, approximately $200 million is attributable to genital warts, $300-400 million to 
invasive cervical cancer, and the rest to routine cervical cancer screening. (16)  
Several models have been developed to evaluate both the public health and monetary 
impact of the HPV Vaccine in the United States. Goldie et al utilized a Markov model; a 
mathematical model that hypothetically follows 100,000 adolescent girls through their 
lifetime and estimates probabilities of transitioning between several health states (i.e. not 
infected, infected with one or more subtypes of HPV, exhibiting degrees of cytologic 
change on Pap smear, degrees of invasive cancer, etc) to determine endpoints such as 
quality-adjusted life years (QALY) gained and total cost. This type of modeling requires 
certain assumptions; in the case of Goldie et al, assumptions were made of 90% vaccine 
efficacy and achievement of full series vaccination in all girls at age 12. (17) 
Goldie et al estimated an absolute lifetime risk of cervical cancer of 3.64% in the 
absence of any screening and a 0.86% risk with current screening practices. They were 
then able to show that full series vaccination of girls at 12 years of age against HPV 
subtypes 16 and 18 would lead to a decrease in the absolute lifetime risk of cervical 
cancer to 0.30-0.47%. The incremental cost-effectiveness of this vaccine (above current 
screening practices) would range from $20,600 (with 100% vaccine efficacy) to $33,700 
(70% vaccine efficacy) per QALY. Other studies have used dynamic transmission models 
which incorporate the benefits of herd immunity, finding a 75% reduction in cervical 
cancer incidence at a much lower cost of $3,000 per QALY. (18). All cost effectiveness 
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assays are sensitive to variables such as duration of vaccine coverage, vaccine cost, and 
frequency of cervical cancer screening.  
Further comparisons by Goldie et al of different combinations of prevention 
strategies (screening plus vaccination, screening alone, etc) were made, and the study 
determined the most effective strategy (with a cost effectiveness ration of less than 
$60,000 per QALY) to be vaccination at 12 years of age accompanied by triennial 
cytologic screening beginning at 25 years. This strategy would reduce the lifetime risk of 
cervical cancer by 94% compared to no screening; by comparison, vaccination with 
annual screening starting at age 18 years would cost more than $3.5 million per QALY.   
The study reports that the proposed strategy of vaccination at 12 years with 
triennial pap screening is more effective than current screening practices and represents 
the best combination of cost and benefits. Most notably, it is a combination of prevention 
of costly high grade lesions and a lessening of the frequency of Pap smears required after 
vaccination that contributes to its cost-effectiveness in the US. This analysis of cost per 
QALY would obviously differ greatly in nations where screening practices are much less 
widespread and presentation of invasive cancers more common.   
Even within the United States, a reduction in HPV acquisition would have a 
particularly strong impact on the low income and minority women who tend to be 
disproportionately affected by cervical cancer, improving their quality adjusted life 
expectancy years in a cost-effective manner. (19) According to data from the National 
Cancer Institute SEER Statistics from 2000-2004, the rate of cervical cancer is 
considerably high in Hispanic (13.8 per 100,000 women) and Black (11.4 per 100,000) 
women than in Caucasian women (8.5 per 100,000). Black and Hispanic women were 
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also more likely to die from cervical cancer than white women (mortality rates of 4.9 and 
3.3 per 100,000 respectively). (20, 20) One explanation for racial disparities in incidence 
is differences in access to screening. A program that incorporates primary prevention 
through vaccination could therefore help to eliminate some of the racial disparities in 
cervical cancer in the United States. (16) 
H. Current Knowledge of Vaccine Acceptability and Barriers to Vaccination 
Despite the compelling data on the vaccine’s efficacy and cost-effectiveness, 
formidable barriers to its universal adoption exist. A New England Healthcare Institute 
expert panel estimate suggests that the full series adoption rate amongst the initial target 
population will be only 15% in the first year.(19) Cited barriers to adoption include lack 
of knowledge about HPV, resistance to vaccinating minors, concern over school or 
government mandates for vaccination, and worries about vaccine safety.[5-9] (21)(21-25) 
An understanding of the role that education can play in influencing public acceptability 
towards vaccination is thus critical to ensure that the vaccine reaches its maximum public 
health potential.  
To date the literature has yielded mixed results regarding the effects of education 
on public acceptability of vaccination. Lascano-Ponce et al showed that following being 
given information about HPV, a high percentage (83.6%) of Mexican women indicated 
they would allow their daughters participate in a trial of the HPV Vaccine; however, pre-
education acceptance was not reported. (26)  
Within the US, Dempsey et al randomized an educational sheet to half of 1600 
parents of 8 to 12 year olds who were mailed a survey about HPV vaccination. Analysis 
of the 840 returned surveys found no significant differences in acceptability between 
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those given the educational sheet and the control group. (27) In comparison Davis et al 
did find a difference in acceptability post education. Parents were given an information 
sheet addressing prevalence of infection, mode of transmission, and severity of sequelae. 
After reading the materials, 37 % of parents of 10-15 year olds who were initially 
opposed to the vaccine changed their mind and 65% of undecided parents became in 
favor of vaccination.(28) Other qualitative studies have assessed general parental 
attitudes towards vaccination (especially towards vaccination for a sexually transmitted 
infection) and have found that in general parents are accepting of health 
recommendations that will protect their children, regardless of the mode of transmission 
of infection.(29, 30) Of note the majority of these studies were done prior to vaccine 
availability and the concurrent increase in media coverage both for and against the 
vaccine. 
I. Vaccine Mandates and Public Opinion 
Over 20 states in the US are currently considering laws to make HPV vaccination 
mandatory for pre-teen girls.  The law governs that individual states and not the federal 
government have the authority to mandate vaccines. This has led to legislative debate on 
the individual state level involving both liberal and religious conservative groups. A 
storm of debate was initiated in Texas after the Republican Governor issued a mandate 
for vaccination of girls entering the 6th grade. The legality of this mandate is now being 
challenged by the state’s attorney general on the basis that it infringes upon parental 
rights and may promote promiscuity. Legislation has already been defeated in 
Mississippi, West Virginia, Kentucky and New Mexico. (31-34) Though the New Mexico 
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legislation passed through the state House and Senates, it was ultimately vetoed by the 
state’s Democratic governor  
  Prior reports addressing school mandates have been in the form of editorials and 
polls.  The National Poll on Children’s Health included in 48 states reported that 45% of 
parents support school mandates for HPV vaccination as compared to 68% parental 
support for a new teen vaccine that prevents tetanus, diphtheria and whooping cough 
(Tdap). (35) Opponents for HPV vaccination cite state legislation as an unwarranted 
intrusion on individual and parental rights. Proponents of mandating vaccination suggest 
that an “opt out” clause (by which parents can choose to opt out of mandated vaccination 
on religious or personal grounds) preserves parental autonomy while also promoting 
widespread achievement of public health goals. 
Various groups have cited concerns that the vaccine would encourage sexual 
promiscuity amongst teens. Implicit in this is the idea that acknowledging teen sexuality 
is to promote it. Furthermore, teens are far more likely to react to the more immediate 
threats of AIDS or pregnancy in determining sexual action than to the remote risk of 
cervical cancer from HPV and the fact that they are protected from it.(32)   
Opponents to mandating vaccination suggest abstinence as an easy and safe 
alternative. Data from the CDC shows that while only 13% of American girls are 
sexually experienced at 15, by 17 this number climbs to 43%, and by 19 years of age to 
70%.  Studies have also shown that abstinence only education does not necessarily delay 
or decrease the onset of sexual activity amongst teens. 
Other arguments against vaccination cite the limited data on the longevity of 
protection offered by the vaccine and its unknown long term effects. It has been reported 
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that in many cases pediatricians have restricted themselves to educating and counseling 
objecting families, since the risks posed by going unvaccinated are not considered a 
danger to the health of communities given the mode of transmission. (32, 35) 
II. Objective 
It was our objective to determine whether use of a multimedia educational tool, 
given the current climate surrounding the HPV vaccine, could affect the following: 1) 
Individual vaccine acceptability 2) Parental vaccine acceptability and 3) Parental views 
on vaccine mandates, school vaccination, and acceptable age for vaccination. A 
secondary objective included identifying whether acceptance post education varied 
amongst ethnic, socioeconomic, and religious/cultural subgroups. 
III. Methods 
Surveys for this cross-sectional, voluntary study were distributed to 256 women 
between the ages of 18 and 60 during a period extending from January to March 2007. 
Institutional approval was obtained from the Partners Institutional Review Board 
committee. Subjects were recruited from the following sites: Brigham and Women’s 
Obstetrics and General Gynecology Clinics, Pap Smear Evaluation Clinics at both 
Brigham and Women’s and Massachusetts General Hospitals, and the REACH 2010 
Coalition of the Boston Public Health Association.  
Those recruited from clinic sites were approached while in the waiting area by a 
bilingual research team member and asked to participate. All study materials were 
available in both English and Spanish. Subjects who agreed to participate (258) 
completed a 32-question initial assessment addressing general knowledge and beliefs 
about HPV as well as a section on demographic information and sections addressing both 
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parental and individual vaccine acceptability. These subjects were then asked to watch an 
eight-minute video about HPV and the vaccine. The educational video used was 
produced by the research team and consists of 3 segments addressing: 1) facts about HPV 
and transmission 2) prevalence and incidence of HPV and 3) information about the 
vaccine. [Table 5]. Those that watched the video (186 subjects) then completed an 
additional 11-question post-survey assessment.  
 
Table 5 Educational Video Content 
Section I 
What is HPV? 
How is HPV transmitted? 
How does HPV lead to cervical cancer & genital warts?
What can you do about HPV? 
Section II 
How common is HPV? 
How and when are youth affected by HPV? 
What are risk factors for acquiring HPV? 
Section III 
What is a vaccine? 
What does the HPV vaccine protect against? 
What are the side effects of the vaccine? 
How is it given? 
Who can get it? 
 
 
 Five questions were extracted from pre and post questionnaires to evaluate HPV 
vaccine acceptability. These questions would address whether participants would 1)self-
vaccinate 2) vaccinate their children 3)support making the vaccine mandatory for all 
children 4)vaccinate their children if the vaccine were free and lastly subjects were asked 
to identify 5)the youngest age at which they would vaccinate their children. Primary 
statistical analysis of the data was performed using the McNemar test to evaluate the 
effectiveness of the video intervention. Secondary analyses were performed using the Chi 
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squared and Fisher’s Exact tests to determine whether specific factors played a role in 
acceptability.  
IV. Results 
Of the 256 subjects that participated in the study, 73% (n=186) completed the 
video intervention and surveys.  Eighty percent (n=150) of the subjects had heard of 
HPV, while 65% (n=120) of subjects knew the HPV vaccine was available prior to 
viewing the video. The demographics of the study population are listed in Table 1. The 
majority of study participants identified as Black or Hispanic (55%), with 27 % self-
identifying as Caucasian.  
Participants were primarily single (43%), working individuals (57%) who had 
some college education (40%).   Sixty percent admitted to being part of a Christian 
religious sect. Sixty-six percent of our participants had an overall combined annual 
income that was less than $50,000.   
 
 23
 
Table 6 Demographic Information (n=178) 
Demographic Characteristics n (%) 
Median Age, years (mean,standard deviation) 30 (33, 11)
Income ($)  
10,000 – 20,000 66 (39.3) 
20,000 – 50,000 55 (32.7) 
50,000 and greater 47 (26.4) 
Race  
Hispanic 66 (40) 
Black 28 (17) 
Caucasian 10 (6) 
Other 61 (34) 
Education  
Grades 1-12 23 (13) 
High School Graduate 32 (18) 
Some College 57 (32) 
College Graduate 39 (22) 
Graduate School 26 (14.6) 
Religion  
Roman Catholic 65 (39) 
   Protestant (Christian) 43 (25) 
Jewish 5 (2.8) 
Other 33 (18.5) 
Not Religious 23 (12.9) 
Marital Status  
   Not Married 78 (45) 
   Living with partner 34 (20) 
   Married or Partnered 51 (29) 
Divorced or Separated 9 (5) 
Widowed 2 (1) 
Work  
Currently Working 100 (58) 
In School 25 (15) 
Homemaker 14 (8) 
Unemployed 19 (11) 
Retired 4 (2) 
Disabled 9 (5) 
Children  
Have Children, mean number of kids 96 (57), 2
No Children 74 (43) 
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Prior to the intervention 67% (n=124) of subjects were willing to receive the 
vaccine for themselves, and 67% (n=124) indicated they would vaccinate their child if the 
vaccine were free [Table 7],.  Fifty-five % (n=102) agreed that the vaccine should be 
required for all children, while 51% (n=95) would agree to vaccination at school.  
After watching the video, individual acceptability increased to 78% (p=.0014) and 
parental acceptability of free vaccination for children increased to 87 percent (p<.0001). 
Support for making the vaccine mandatory and administering it in school also increased 
to 73% (p<.0001) and 65% (p<.0001) respectively.   [Figure 2]  
Figure 2 Vaccine Acceptability Pre and Post Video 
Intervention
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Table 7 Vaccine Acceptability Pre and Post Video Intervention 
 Pre-Intervention 
(n=186) 
Post-Intervention 
(n=186) 
P-value 
Would you vaccinate yourself? 67% (124) 78% (145) 0.0014 
Would you make the vaccine required 
for all children? 
55% (102) 72% (135) <0.0001 
Would you vaccinate your child if it 
were given at school? 
51% (95) 65% (121) <0.0001 
Would you vaccinate your child if it 
were free? 
67% (124) 86% (161) <0.0001 
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Prior to intervention, the acceptable age of vaccination was 16 years or older in 56 
% of subjects. After the intervention, 82.3 % (p<.0001) of subjects were willing to accept 
vaccination of children starting from age 9 and up. [Fig 3]  
Figure 3 Acceptable Age of Vaccination Pre and Post 
Study
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Secondary analysis revealed that Hispanic, Blacks and those with combined 
income less than $ 50,000 were the subgroups that were more likely to initially decline 
the vaccine but after the intervention were the groups most likely to accept vaccination 
for their children. [Figures 8 & 9] Of the subgroups who did not accept the vaccine and 
those who changed their minds after the video, the perception that the vaccine would 
promote sex did not seem to play a role in acceptability.  In fact the majority of 
participants (62%) did not believe the vaccine would promote sexual activity in young 
people (n=114/183).  Sixty-one percent (n= 113/186) of participants had children, and of 
these parents 44 % (n=50/113) said they talked to their children about sex. Whether the 
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participants talked to their children about sex and whether they had children did not affect 
acceptability. 
Table 8 Change in Acceptability by Ethnic Group 
  Caucasian Hispanic Black Other/No 
response 
Total Fisher’s 
Exact 
Test 
Group 
1* 
7 1 7 3 18 Would you 
vaccinate 
your child 
if the 
vaccine 
were free? 
Group 
2* 
6 13 22 3 44 
0.0287 
 
Table 9 Change in Acceptability by Income Level 
  0-20K 21K-
50K 
51K+ No 
response 
Total Fisher’s 
Exact 
Test 
Group 
1* 
4 6 7 1 18 Would you 
vaccinate 
your child 
if the 
vaccine 
were free? 
Group 2* 20 17 5 2 44 
0.0723 
* Group 1 = would not give vaccine even after video. Group 2 = initially said no but changed to yes post 
video. 
 
 Eighty-three percent (n=154/186) of participants were able to name at least one of 
the following correct answers when asked what HPV causes: genital warts, precancerous 
changes (cervical dysplasia), abnormal pap smears, cervical cancer, or cancer of the 
vagina. There was no significant difference between Hispanics, Blacks, and Caucasians 
in their ability to answer this question correctly.  
Amongst the questions answered by all participants (n=256) and not just those 
completing the video, we found that the majority of participants (64%, 165/256) thought 
the vaccine should be available for both men and women. Participants identified the 
following as very important in their decision to get a vaccine: safety (n=234/256, 91%), 
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side effects (214/256, 84%), and how long it would last (178/236, 70%). Ease of access, 
number of doses, and cost followed in importance. When asked where they would go for 
more information about the vaccine, 85% (n=218/256) said they would go to their doctor, 
while 70% (n=178/256) cited the internet.   
V. Discussion  
 In order to maximize the impact of the Human Papillomavirus Vaccine, policy-
makers will need a broad understanding of both current public acceptance and potential 
barriers to vaccination. Our study found high initial individual and parental (66 and 68 % 
respectively) acceptance of vaccination amongst a diverse urban sample of women aged 
16 to 80.  
These numbers correspond generally to high rates of acceptability found by 
previous studies. Most recently (but still prior to vaccine availability), Slomovitz et al 
found individual and parental acceptance rates of 77% and 67% in a population of urban 
Texan women.(36) A prior study by Davis of 575 parents of 10 to 15 year olds found a 
pre-education acceptance rate of 55 percent, and an earlier study in 2003 by Kahn et al of 
52 female parents found even higher individual and parental acceptance (85% and 83% 
respectively).(28, 37) These relatively high rates of vaccine acceptability help to mitigate 
claims that the public acceptance serves as a significant barrier to vaccine delivery.  
Moreover, our study suggests that public opinion can be influenced by directed education 
from media sources. Use of a multi-media instrument in the form of an educational video 
significantly increased overall individual and parental acceptability to 78 and 87%, 
respectively.  It is possible that the mixed results obtained by previous studies (26-28, 37) 
on the effect of education could reflect the mode of education used; multimedia methods 
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may influence acceptability more than written materials. We find it particularly 
encouraging that after viewing our video, parents were significantly more willing to 
vaccinate children at younger ages (age 9 and above versus age 16). Given that the 
vaccine is maximally effective when administered prior to the onset of sexual activity, 
vaccinating children at a younger age would improve target efficacy. 
Our study suggests that public opinion of a vaccine mandate could also be 
influenced by education.  Although only 55% of our population initially supported 
mandatory vaccination with only 51% approval of vaccination in school, following 
viewing our video vaccination approval rates rose to 72% and 65% respectively. 
Although this is true, the lowest rate of acceptability was found with in school 
vaccination, which may indicate that this is something the public may not be ready for. 
As for the concern that the vaccine could promote sexual activity, a great deal of 
research supports the claim that sex education and condom distribution do not lead to an 
increase in sexual activity.  Studies have shown that comprehensive sex education 
actually reduces the frequency of sex, delays initiation of sexual intercourse and reduces 
the number of sexual partners. [18-20]. Over half (62%) of all participants in this study 
did not believe the HPV vaccine would lead to increased sexual activity among 
recipients. In light of the fact that a great deal of media attention has been devoted to 
claims that the vaccine could encourage sexual activity in teens, the fact that the majority 
of our study population did not feel this to be the case is encouraging.  
The question of cost still seems to be an important one within the HPV 
vaccination debate.  Who will pay for the mandated vaccine?  Policy makers have not 
answered the question if consumers, insurers, federal agencies, or states will bear the 
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cost. Our study revealed that the greatest change and increase in acceptance for 
vaccination for children in the context of free vaccination. Though individuals did not 
rank cost very highly amongst factors that would influence their willingness to receive a 
vaccine (safety, side effects, and duration of protection were most important), it no doubt 
plays a role.  Finding a way to address cost issues will be important to help ensure broad 
spectrum access.  
Aggressive marketing campaigns by Merck for Gardasil nationwide have no 
doubt played a role in increasing public knowledge and awareness of the need for HPV 
vaccination. The positive ramifications of this are evident in our study, as 81 percent of 
the study population was able to name correctly at least one sequelae of HPV infection. A 
review of media representation of HPV by Calloway et al found that ads were not always 
specific in clearly explaining the connections between HPV and Cervical Cancer. [15] It 
is for this reason that we advocate the development of other media tools to educate about 
HPV and ensure that women understand the links between HPV, abnormal Pap smears, 
genital warts, and cervical cancer.  
Our educational intervention also demonstrated that lower income, minority 
populations may be the best target population to affect change in attitudes towards the 
HPV vaccine using this educational tool.  Our experience revealed that utilization of 
video as a way to educate helped keep the individual focused and interested in the 
material and addressed misunderstandings of information presented by use of visual aids.   
This may be more effective in subgroups where public-based health clinics service lower 
income or less educated populations. 
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Our data showed that a novel approach of educational intervention by video improved 
rates of parental vaccine acceptability, in a minority, predominantly underserved 
population. Nevertheless, this study may have been influenced by several factors, 
including selection bias whereby the majority of participants were solicited from a 
gynecology and gyn-specific colposcopy clinic. These subjects may have been sensitized 
to the impact of HPV and the possible influence of the HPV vaccine, more than a 
population solicited in a different community setting. Although the participation rate was 
relatively high at 73%, they may also have been more inclined to participate within the 
setting of a gynecology clinic than at a local community site. These results may not be 
directly applicable to the general population.  
Furthermore, since all subjects were female, the knowledge and acceptance rate of 
males of this same topic remains unknown. We cannot speculate on whether fathers 
would be as knowledgeable or inclined to support vaccination of their daughters. 
Additionally, we have not tested whether other intervention methods such as books, 
pamphlets, posters, or acoustic means such as through radio-ads would be as affective. 
Although our video did show a significant increase in parental vaccine acceptability after 
viewing, this intervention method may not be entirely practical or feasible in all settings. 
We also do not know if large scale application of our video intervention would produce 
the same effect as that viewed intimately on a laptop or within a small group setting as 
was done in this study.  
 In order to determine the full utility of a video intervention to increase 
acceptability of the HPV vaccine, a larger study targeted to both women and men of a 
variety of ages, of racial and social backgrounds, and from a variety of community 
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settings may help us answer the questions posed above. In this manner, we may better 
identify and target the populations most vulnerable to developing cervical dysplasia and 
cancer.  
 The HPV vaccine represents a rare public health opportunity to protect a large 
cohort of individuals from a devastating illness, not to mention the psychological and 
economic tolls of screening practices. Achieving target levels of vaccination will require 
sophisticated programs to counter barriers such as cost, access, and individual 
acceptance. Our study suggests that education, in this case through multimedia, can have 
a powerful effect on the latter. Thus, by utilizing this information to develop appropriate 
educational tools, we can directly impact rates of cervical dysplasia, genital warts, and 
cervical cancer in the near and distant future. 
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Appendix I. Sample Survey 
 
1. Please Circle:         MALE          FEMALE 
2. I have heard of a virus called Human Papillomavirus (HPV). Please circle:    Yes  No  Not Sure
 
3. Can you be tested for Human Papilloma Virus (HPV)? 
 
 Yes 
 No 
 I don’t know 
 
4. What does HPV cause? (Circle all that you think apply) 
   Genital Warts 
    
   Herpes 
 
   Precancerous Changes  
   (Cervical Dysplasia) 
  
  Cervical Cancer 
 
  I Don’t Know 
    
Infertility (cannot have children) 
      
 Premature Birth 
 
 Abnormal PAP smears 
 
 AIDS 
 
Cancer of the Vagina 
 
5. Do you know what a Pap smear tests for?   Yes 
 No 
 Not Sure 
6. ONLY ANSWER IF YOU SAID YES TO 
QUESTION 4:  what does a Pap smear check for? 
Mark all that might apply. 
 Chlamydia or Gonorrhea 
 Pre-Cancerous Cells 
 Cervical Cancer 
 Fertility 
 Yeast Infections 
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7. How is HPV spread from one person to another? (Circle all that you think apply)
 
   Kissing 
    
   Close skin contact without  
   sexual intercourse 
 
  Oral Sex 
    
  I Don’t Know 
  Anal Sex 
 
  Sexual Intercourse 
 
  Sitting on public toilets 
    
  From someone’s cough 
 
  
8. Condoms prevent spread of HPV. 
 Always 
 Sometimes 
 Never 
 I don’t know 
9. Taking the birth control pill prevents you from getting  
infected with HPV. 
 Yes 
 No 
 I don’t know 
10. Have you ever had a sexually transmitted disease? 
 Yes 
 No 
 Not Sure 
11. FOR WOMEN ONLY: Have you ever been told you had 
an abnormal Pap smear and/or precancerous change? 
 Yes 
 No 
 I don’t know 
12. FOR WOMEN ONLY: Have you had cervical cancer? 
 Yes 
 No 
13. Have you or any of your family members had cancer? 
 Yes 
 No 
 I don’t know. 
14. Have you talked to your child about sex? 
 Yes 
 No 
 Don’t have kids 
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15. Who talks to your children about sex? (mark all that apply) 
  Myself 
    
   Child’s School 
 
   Church group or religious 
leader 
   Other youth activity     
programs 
 
   Media (TV or radio or 
internet) 
   Child’s Doctor 
 
   My kids are too 
young to talk about sex 
  
  Other: 
__________________ 
 
16.  If you have not talked to your children about sex, why not? 
  My child is too young. 
    
   Someone else has talked 
to them already. 
 
  My child’s school will talk 
to them. 
   I am not comfortable 
talking to them about sex. 
 
   I have no time to talk 
to them about sex. 
   My child will not 
listen to me 
  
  Other: 
__________________ 
 
17. I knew before today that there is an HPV vaccine. 
 Yes 
 No 
 I’m not sure 
18. Who do you think the vaccine should be for? 
 Women only 
 Men only 
 Women and Men 
 Should not be 
available. 
19. What is the youngest age you would give your child the 
vaccine?   
 9 
 10-12 
 13-15 
 16-18 
 Older than 18 
 Not Sure 
 I would not give 
my child the vaccine. 
20. Would you vaccinate your child if the vaccine is free? 
 Yes 
 No 
 I’m not sure 
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21. Would you vaccinate your child if the vaccine were 
given at school?  
 Yes 
 No 
 I’m not sure 
22. If your doctor recommends the HPV vaccine would you  
give it to your child? 
 Yes 
 No 
 I’m not sure 
23. Would you support making the HPV vaccine required  
for all children? 
 Yes 
 No 
 I’m not sure 
24. Do you think giving young people the HPV vaccine will  
make them more likely to have sex? 
 Yes 
 No 
 I’m not sure 
25. How would you describe the HPV vaccine to your child? Mark all that apply. 
  It prevents cervical cancer. 
    
   It prevents a sexually 
transmitted disease. 
   All girls get the 
vaccine. 
 
   It prevents women’s 
diseases, 
   Not sure 
  
  Other: 
__________________ 
 
26. If you answered “not sure” to questions 17-23, is it because you don’t know 
enough about the HPV vaccine?   
 Yes       No       Other reason (please explain: _______________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
27. (FOR MEN AND WOMEN BOTH) Would you  
get the vaccine yourself? 
 Yes 
 No 
 I am not sure  
28. Would you get the vaccine to protect your 
partner(s)?   
 Yes 
 No 
 I am not sure 
29. If your doctor recommends the HPV vaccine  
would get it? 
 Yes 
 No 
 I am not sure 
 36
30. Would your partner (husband, wife, boyfriend or 
girlfriend) support your decision to get the HPV 
vaccine? 
 Yes 
 No 
 I am not sure 
31. How important are the following items when you think about getting a 
vaccine? 
 Very Important Neutral Not Important 
Safety    
How Easy it Would be to Get It    
Side Effects    
Number of Doses I Would Need    
Cost    
How Long it Lasts    
32.  Where would you go to find out more about the HPV vaccine?  (Mark all that 
apply) 
 Radio  Friend  Church group 
 Internet  Community Group  Doctor 
 Television  Other people of the same race only. 
 Child’s doctor 
(pediatrician) 
 Library  School Staff  Other family members 
  Other extended family members 
 I would not look for any 
more information.  
 Other: _____________________________________________________________ 
After learning more about HPV, please answer questions below: 
 
1. Who do you think the vaccine should be  
     for? 
 Girls only 
 Boys only 
 Boys and Girls 
 Should not be available. 
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2. What is the youngest age you would give your child 
the vaccine? 
 9 
 10-12 
 13-15 
 16-18 
 Older than 18 
 Not Sure 
 I would not give my child 
the vaccine. 
3. Would you vaccinate your child if the vaccine  
is free? 
 Yes 
 No 
 I’m not sure 
4. Would you vaccinate your child if the vaccine  
is given at school?  
 Yes 
 No 
 I’m not sure 
5. Would you support making the vaccine required  
for all children? 
 Yes 
 No 
 I’m not sure 
6. If your doctor recommends the HPV vaccine would 
you give it to your child? 
 Yes 
 No 
 I’m not sure 
7. Do you think giving young people the HPV vaccine 
will make them more likely to have sex? 
 Yes 
 No 
 I’m not sure 
8. How would you describe the HPV vaccine to your child? Mark all that apply. 
  It prevents cervical cancer. 
    
   It prevents a sexually 
transmitted disease. 
   All girls get the 
vaccine. 
 
   It prevents women’s 
diseases, 
   Not sure 
  
  Other: 
__________________ 
 
9. Would you get the vaccine yourself? 
 Yes 
 No 
 I am not sure  
10. Would you get the vaccine to protect your 
partner(s)? 
 Yes 
 No 
 I am not sure 
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11. How important are the following items when you think about getting a 
vaccine? 
 Very 
Important 
Neutral Not Important 
Safety    
How Easy it Would be to Get It    
Side Effects    
Number of Doses I Would 
Need    
Cost    
How Long it Lasts    
 
 
Demographics  (Information for survey purposes only) 
1. What is your age? _________________ 2.  Please circle:   Female     Male 
 
3. What is your marital status? 
 Not married      
Living with partner but not married   
 Currently married or partnered 
 Divorced or legally separated 
 Widowed 
4. What is your ethnic background? 
   Latina or Hispanic: 
        Cuban 
        Dominican 
        Puerto Rican 
        Central American 
        South American 
        Mexican  
        Other: ________ 
 
   African American 
   Native American 
   Native Hawaiian 
   Other Ethnic Group: 
____________________ 
   Caribbean/West 
Indian: 
        Haitian 
        Jamaican 
        Trinidadian 
        Other: 
___________________ 
 
   Asian: 
        Vietnamese 
        Cambodian 
        Laotian 
        Chinese 
        Japanese 
        Indian 
        Other: 
___________ 
   European: 
        Irish 
        Italian 
        Russian 
        Other: 
___________ 
   Jewish 
 Middle Eastern 
   African: 
     Somalian 
     Nigerian 
     Senegalese 
     Cape Verdean 
     Other: 
___________ 
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5. What is your zip code?   
6. What is your highest level of education? 
 No formal school 
 Grades 1-12 (primary) 
 High school graduate (secondary) 
 Some college 
 College graduate  
 Graduate School 
 Vocational/ Tech school 
7. Which of the following best describes your 
work? 
 Currently Working 
 In School (Student) 
 Homemaker (housewife) 
 Unemployed (not working) 
 Retired 
 Extended Sick Leave 
 Disabled 
 Other: _____________________ 
8. If you are currently working, what do you do? 
   Retail Store Clerk 
 
   Healthcare Support    
  (Home Health Aid, Nurse’s   
  Aid, Medical Assistant) 
 
   Protective Services    
  (Firefighter, Police Officer) 
 
   Food Preparation &   
  Serving (cook, fast food  
  restaurant work). 
 
   Building, Grounds       
  Cleaning, & Maintenance 
  Management 
 
  Business and Financial
 
   Computer and  
  Mathematical  
 
   Architecture and   
  Engineering 
 
   Life, Physical, & 
  Social Science 
 
   Legal Occupations 
  Community &  
  Social Services 
 
   Education,  
  Training & Library 
 
   Arts, Design,   
  Media, Sports &  
  Entertainment 
 
   Healthcare  
  Practitioners and  
  Technical  Work 
 
  Other 
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8. What is your total annual household  
income? 
 
 Less than $10,000 
 $10,000 to $20,000 
 $21,000 to $30,000 
 $31,000 to $50,000 
 $51,000 to $100,000 
 Over $100,000 
9. (WOMEN ONLY) Where do you get your  
Pap test? 
 I don’t know what a Pap test is. 
 Primary Care Doctor 
 Ob-Gyn 
 I don’t get Pap tests. 
 Pediatrician 
 Other___________________ 
10. What type of heath insurance do you 
currently have? 
 Medicare 
 Medicaid or Mass Health? 
 Private Insurance through my 
work or my spouse’s work. 
 Get free care. 
 I do not have health insurance. 
11. What is your religion? 
 Roman Catholic 
 Jewish 
 Protestant (Christian) 
 Muslim 
 Not Religious 
 Other: _____________________ 
12. How much does your faith, religion affect 
your decisions about health? 
 Not at all 
 Somewhat (a little) 
 Most of the time 
 Affects all my health decisions 
13. Do you have children?    Yes      No
If yes, please answer questions 14 and 15. 
14. How many children do you have? 
__________ 
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15.  Please list your children by age and if they are a girl or boy. 
Age 
Boy Girl 
1.    
2.    
3.   
4.   
5.   
6.   
7.   
8.    
15. I give my children all the vaccines 
recommended by their doctor.  Yes       No       Sometimes 
 
 42
VI. References 
 
1. Dasbach, E.J., Elbasha, E.H., and Insinga, R.P. 2006. Mathematical models for 
predicting the epidemiologic and economic impact of vaccination against human 
papillomavirus infection and disease. Epidemiol Rev 28:88-100 28:88-100.  
2. Lehtinen, M., Apter, D., Dubin, G., Kosunen, E., Isaksson, R., Korpivaara, E.L., Kyha-
Osterlund, L., Lunnas, T., Luostarinen, T., Niemi, L. et al. 2006. Enrollment of 
22,000 adolescent women to cancer registry follow-up for long-term human 
papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 
17(8):517-21 17:517-21.  
3. Dunne, E.F., Unger, E.R., Sternberg, M., McQuillan, G., Swan, D.C., Patel, S.S., and 
Markowitz, L.E. 2007. Prevalence of HPV infection among females in the United 
States.[see comment]. Jama 297(8):813-9 297:813-9.  
4. Weller, S.C., and Stanberry, L.R. 2007. Estimating the population prevalence of 
HPV.[comment]. Jama 297(8):876-8 297:876-8.  
5. Kahn, J.A., Lan, D., and Kahn, R.S. 2007. Sociodemographic factors associated with 
high-risk human papillomavirus infection. Obstet. Gynecol. 110:87-95.  
6. Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., and Wacholder, S. 2007. 
Human papillomavirus and cervical cancer. Lancet 370:890-907.  
7. Sherman, M.E., Wang, S.S., Carreon, J., and Devesa, S.S. 2005. Mortality trends for 
cervical squamous and adenocarcinoma in the United States. Relation to incidence 
and survival. Cancer 103:1258-1264.  
8. Mantovani, F., and Banks, L. 2001. The human papillomavirus E6 protein and its 
contribution to malignant progression. Oncogene 20:7874-7887.  
9. Anonymous ACS :: Detailed Guide: Cervical Cancer. 2008.  
10. Petignat, P., and Roy, M. 2007. Diagnosis and management of cervical cancer. BMJ 
335:765-768.  
11. Lai, C.H., Huang, K.G., Hong, J.H., Lee, C.L., Chou, H.H., Chang, T.C., Hsueh, S., 
Huang, H.J., Ng, K.K., and Tsai, C.S. 2003. Randomized trial of surgical staging 
 43
(extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical 
cancer. Gynecol. Oncol. 89:160-167.  
12. Lagasse, L.D., Creasman, W.T., Shingleton, H.M., Ford, J.H., and Blessing, J.A. 
1980. Results and complications of operative staging in cervical cancer: experience 
of the Gynecologic Oncology Group. Gynecol.Oncol. 9:90-98.  
13. Mao, C., Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Wiley, D.J., 
Alvarez, F.B., Bautista, O.M., Jansen, K.U., and Barr, E. 2006. Efficacy of human 
papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized 
controlled trial. Obstet. Gynecol. 107:18-27.  
14. Villa, L.L., Ault, K.A., Giuliano, A.R., Costa, R.L., Petta, C.A., Andrade, R.P., 
Brown, D.R., Ferenczy, A., Harper, D.M., Koutsky, L.A. et al. 2006. Immunologic 
responses following administration of a vaccine targeting human papillomavirus 
Types 6, 11, 16, and 18. Vaccine 24:5571-5583.  
15. Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R., 
Wheeler, C.M., Koutsky, L.A., Malm, C., Lehtinen, M. et al. 2005. Prophylactic 
quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle 
vaccine in young women: a randomised double-blind placebo-controlled multicentre 
phase II efficacy trial. Lancet Oncol. 6:271-278.  
16. Markowitz LE. Dunne EF. Saraiya M. Lawson HW. Chesson H. Unger ER. Centers 
for Disease Control and Prevention (CDC). Advisory Committee on Immunization 
Practices (ACIP). 2007. Quadrivalent Human Papillomavirus Vaccine: 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR Recomm Rep. 56:1-24.  
17. Goldie, S.J., Kohli, M., Grima, D., Weinstein, M.C., Wright, T.C., Bosch, F.X., and 
Franco, E. 2004. Projected clinical benefits and cost-effectiveness of a human 
papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. 96:604-615.  
18. Elbasha, E.H., Dasbach, E.J., and Insinga, R.P. 2007. Model for assessing human 
papillomavirus vaccination strategies. Emerg. Infect. Dis. 13:28-41.  
19. Spurgeon, S.A., Johnson, D., Pefole, M., and Fleishman, V. 2006. Challenges in 
Vaccine Policy: A Case Study of the HPV Vaccine. New England Healthcare 
Institute Innovation Series.  
 44
20. Ries, L.A.G., Melbert, D., Krapcho, M., Mariotto, A., Miller, B., Feuer, E.J., Clegg, 
L., Horner, M., Howlader, N., Eisner, M. et al. 2006. SEER Cancer Statistics 
Review, 1975-2004, Cancer of the Cervix. 2008.  
21. Brabin, L., Roberts, S.A., and Kitchener, H.C. 2007. A semi-qualitative study of 
attitudes to vaccinating adolescents against human papillomavirus without parental 
consent. BMC Public Health 7:20 7:20.  
22. Constantine, N.A., and Jerman, P. 2007. Acceptance of human papillomavirus 
vaccination among Californian parents of daughters: a representative statewide 
analysis.[see comment]. J Adolesc Health 40(2):108-15 40:108-15.  
23. Kahn, J.A. 2007. Maximizing the potential public health impact of HPV vaccines: a 
focus on parents.[comment]. J Adolesc Health 40(2):101-3 40:101-3.  
24. Brabin, L., Roberts, S.A., Farzaneh, F., and Kitchener, H.C. 2006. Future acceptance 
of adolescent human papillomavirus vaccination: a survey of parental attitudes. 
Vaccine 24(16):3087-94 24:3087-94.  
25. Colgrove, J. 2006. The ethics and politics of compulsory HPV vaccination. N Engl J 
Med 355(23):2389-91 355:2389-91.  
26. Lazcano-Ponce, E., Rivera, L., Arillo-Santillan, E., Salmeron, J., Hernandez-Avila, 
M., and Munoz, N. 2001. Acceptability of a human papillomavirus (HPV) trial 
vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch. Med. Res. 
32:243-247.  
27. Dempsey, A.F., Zimet, G.D., Davis, R.L., and Koutsky, L. 2006. Factors that are 
associated with parental acceptance of human papillomavirus vaccines: a 
randomized intervention study of written information about HPV. Pediatrics 
117(5):1486-93 117:1486-93.  
28. Davis, K., Dickman, E.D., Ferris, D., and Dias, J.K. 2004. Human Papillomavirus 
Vaccine Acceptability Among Parents of 10- to 15-Year-Old Adolescents. Journal 
of Lower Genital Tract Disease 8:188-194.  
29. Olshen, E., Woods, E.R., Austin, S.B., Luskin, M., and Bauchner, H. 2005. Parental 
acceptance of the human papillomavirus vaccine. J. Adolesc. Health 37:248-251.  
 45
30. Mays, R.M., Sturm, L.A., and Zimet, G.D. 2004. Parental perspectives on vaccinating 
children against sexually transmitted infections. Soc. Sci. Med. 58:1405-1413.  
31. Udesky, L. 2007. Push to mandate HPV vaccine triggers backlash in USA. Lancet 
369(9566):979-80 369:979-80.  
32. Charo, R.A. 2007. Politics, parents, and prophylaxis--mandating HPV vaccination in 
the United States. N. Engl. J. Med. 356:1905-1908.  
33. Gostin, L.O., and DeAngelis, C.D. 2007. Mandatory HPV vaccination: public health 
vs private wealth. JAMA 297:1921-1923.  
34. Bleakley, A., Hennessy, M., and Fishbein, M. 2006. Public opinion on sex education 
in US schools. Arch. Pediatr. Adolesc. Med. 160:1151-1156.  
35. Singer, D.C., and Davis, M.M. May 2007. Majority of U.S. Parents Not in Favor of 
State HPV Vaccine Mandates. C.S. Mott Children's Hospital National Poll on 
Children's Health 1.  
36. Slomovitz, B.M., Sun, C.C., Frumovitz, M., Soliman, P.T., Schmeler, K.M., Pearson, 
H.C., Berenson, A., Ramirez, P.T., Lu, K.H., and Bodurka, D.C. 2006. Are women 
ready for the HPV vaccine? Gynecol Oncol 103(1):151-4 103:151-4.  
37. Kahn, J.A., Rosenthal, S.L., Hamann, T., and Bernstein, D.I. 2003. Attitudes about 
human papillomavirus vaccine in young women. Int J STD AIDS 14(5):300-6 
14:300-6.  
38. Melnikow, J., Nuovo, J., Willan, A.R., Chan, B.K., and Howell, L.P. 1998. Natural 
history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. 
Gynecol. 92:727-735.  
39. Ostor, A.G., and Mulvany, N. 1996. The pathology of cervical neoplasia. Curr. Opin. 
Obstet. Gynecol. 8:69-73.  
 
